MBX Biosciences, Inc. (MBX)
53.25
-1.29
(-2.37%)
USD |
NASDAQ |
Oct 08, 16:00
53.31
+0.06
(+0.11%)
After-Hours: 20:00
MBX Biosciences Enterprise Value : 2.138B for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 2.138B |
| October 07, 2026 | 2.200B |
| October 06, 2026 | 2.314B |
| October 05, 2026 | 2.392B |
| October 02, 2026 | 2.390B |
| October 01, 2026 | 2.296B |
| September 30, 2026 | 2.396B |
| September 29, 2026 | 2.354B |
| September 28, 2026 | 2.344B |
| September 25, 2026 | 2.156B |
| September 24, 2026 | 2.241B |
| September 23, 2026 | 2.361B |
| September 22, 2026 | 2.557B |
| September 21, 2026 | 2.507B |
| September 18, 2026 | 2.601B |
| September 17, 2026 | 2.648B |
| September 16, 2026 | 2.537B |
| September 15, 2026 | 2.514B |
| September 14, 2026 | 2.437B |
| September 11, 2026 | 2.415B |
| September 10, 2026 | 2.507B |
| September 09, 2026 | 2.601B |
| September 08, 2026 | 2.605B |
| September 04, 2026 | 2.544B |
| September 03, 2026 | 2.530B |
| Date | Value |
|---|---|
| September 02, 2026 | 2.504B |
| September 01, 2026 | 2.506B |
| August 31, 2026 | 2.538B |
| August 28, 2026 | 2.606B |
| August 27, 2026 | 2.768B |
| August 26, 2026 | 2.786B |
| August 25, 2026 | 2.875B |
| August 24, 2026 | 2.768B |
| August 21, 2026 | 2.765B |
| August 20, 2026 | 2.766B |
| August 19, 2026 | 2.865B |
| August 18, 2026 | 2.774B |
| August 17, 2026 | 2.857B |
| August 14, 2026 | 2.873B |
| August 13, 2026 | 2.801B |
| August 12, 2026 | 2.796B |
| August 11, 2026 | 2.750B |
| August 10, 2026 | 2.757B |
| August 07, 2026 | 2.837B |
| August 06, 2026 | 2.803B |
| August 05, 2026 | 2.820B |
| August 04, 2026 | 2.975B |
| August 03, 2026 | 2.673B |
| July 31, 2026 | 2.746B |
| July 30, 2026 | 2.772B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amylyx Pharmaceuticals, Inc. | 2.784B |
| ANI Pharmaceuticals, Inc. | 1.888B |
| Corcept Therapeutics, Inc. | 12.49B |
| Veru, Inc. | 18.15M |
| Johnson & Johnson | 645.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -37.10M |
| Total Expenses (Quarterly) | 37.10M |
| EPS Diluted (Quarterly) | -0.7777 |
| Earnings Yield | -4.52% |
| Normalized Earnings Yield | -4.519 |